Vijaypd Ceutical IPO: All you need to know before subscription – News Air Insight

Spread the love


Vijaypd Ceutical will launch its IPO on September 29 to raise Rs 19.25 crore through a fresh issue of 55 lakh equity shares. The fixed price has been set at Rs 35 per share. The IPO closes on October 1, with allotment scheduled for October 3 and listing expected on October 7 on the NSE SME platform.

Investors can bid in lots of 4,000 shares, requiring a minimum retail investment of Rs 2.8 lakh. As of now, the grey market premium (GMP) stands at zero, suggesting muted listing-day sentiment.

Company overview

Vijaypd Ceutical is engaged in the distribution of pharmaceutical products and consumer goods. The company serves as a representative, dealer, supplier, trader, and stockist for more than 170 healthcare manufacturers, offering over 19,000 SKUs.Its diverse product basket covers medicines (tablets, injections, ointments, capsules), vitamins, enzymes, diagnostic kits, ayurvedic products, cosmetics, food items, and personal care goods.

The company has a strong distribution presence across four districts, reaching over 2,100 pharmacies, clinics, and nursing homes through 20 locations.

Financial strength

Vijaypd Ceutical has reported strong growth in recent years. Revenue nearly doubled to Rs 107.59 crore in FY25 from Rs 54.34 crore in FY24, while profit after tax surged 191% to Rs 4.8 crore from Rs 1.65 crore. EBITDA also rose to Rs 8.59 crore.

Proceeds of the IPO

The IPO proceeds will primarily be used for setting up a pharmaceutical API and intermediates manufacturing plant in MIDC Shrirampur, Ahmednagar (Rs 10.83 crore). Other objectives include repayment of borrowings (Rs 5.1 crore) and general corporate purposes.

Outlook

The high minimum investment size and the absence of a GMP premium point to a cautious stance among investors ahead of the listing.

Add ET Logo as a Reliable and Trusted News Source

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *